Centessa Pharmaceuticals plc.
CNTA.US | N/A
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The co...Show More
Better Health for All
10
Centessa Pharmaceuticals, as a clinical-stage company, has no revenue from commercialized products, resulting in a neutral score for harmful revenue share.
1
The company demonstrates excellent risk transparency by disclosing 109 risk factors in its Q3 2024 earnings report
2
and making program descriptions available on ClinicalTrials.gov and the EU Clinical Trial Information System as required by law.
3
For healthcare data responsibility, Centessa processes data in accordance with EU/UK GDPR,
4
uses pseudonymization,
5
implements security measures to prevent unauthorized access,
6
and retains clinical data for at least 25 years.
7
In clinical trial ethics, the company adheres to strong ethical standards, with independent review boards or ethics committees approving studies
8
and obtaining informed consent from participants,
9
and is required to comply with GCP regulations.
10
Fair Money & Economic Opportunity
0
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering medicines.
1
The provided articles discuss drug trials, financial valuation, and public offerings of shares. There is no evidence that the company engages in financial services, lending, or deposit activities for consumers or businesses. Therefore, all KPIs related to Fair Money & Economic Opportunity are not applicable to its business model.
Fair Pay & Worker Respect
0
No evidence available to assess Centessa Pharmaceuticals plc on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
-20
The company does not procure or trade physical commodities, and outsources its research, development, and testing activities, indicating no material sourcing of at-risk inputs.
1
There is no evidence that any supplier contracts include enforceable ethical-sourcing clauses.
2
While the company has a Code of Business Conduct and Ethics, this applies to its employees, officers, and directors, not explicitly to its suppliers.
3
Honest & Fair Business
0
No evidence available to assess Centessa Pharmaceuticals plc on Honest & Fair Business.
Kind to Animals
-70
The company conducts preclinical studies of its drugs on animals to assess product safety.
1
A convulsion was observed in a single canine at the maximum dose tested in a non-GLP dose range finding study.
2
The company relies on third parties to conduct preclinical studies and clinical trials.
3
There is no evidence of the company employing non-animal testing methods.
4
The company's policy is to conduct preclinical studies on animals, with no public position on animal welfare legislation or stated commitment to reduction.
5
The number of animals used annually is not disclosed, but the company's reliance on animal testing for preclinical studies suggests a significant volume.
6
No War, No Weapons
0
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on developing medicines for various therapeutic areas, including sleep disorders, neurological disorders, hemophilia, and solid tumors.
1
The provided articles, including financial reports and corporate profiles, contain no information indicating any involvement in arms manufacturing, defense contracts, military activities, or dual-use technologies.
2
There is no evidence of revenue from defense contracts, R&D investment in dual-use technologies, sales to any regimes, or any exposure to controversial weapons.
3
The company's core business and operations, as described, do not involve any activities related to the defense sector, military, or conflict zones, rendering all related KPIs as not applicable.
4
Planet-Friendly Business
0
In 2024, the company reported total Scope 1, 2, and 3 greenhouse gas emissions of 19.52 tCO2e, with Scope 1 and 3 emissions at 0 tCO2e.
1
The company states its activities have a minimal environmental impact, operates largely on a virtual basis, and outsources much of its research, development, and testing.
2
It considers itself a 'low energy user' under reporting regulations.
3
To reduce its carbon footprint, the company has increased procurement of electricity from renewable energy providers where possible, adopted automated lighting controls, energy-efficient office equipment, and maintained a hybrid work policy.
4
Key IT systems have been migrated to energy-efficient cloud data centers.
5
Respect for Cultures & Communities
0
No relevant evidence was found in the provided articles pertaining to Centessa Pharmaceuticals plc (CNTA.US) and the ethical value of 'Respect for Cultures & Communities'. The articles either discuss different companies or contain no information relevant to the specified KPIs for CNTA.US.
Safe & Smart Tech
0
No evidence available to assess Centessa Pharmaceuticals plc on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Centessa Pharmaceuticals plc on Zero Waste & Sustainable Products.